This is a summary of the European public assessment report (EPAR) for Cetrotide. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cetrotide.
Therapeutic Indication
### Therapeutic indication Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte-pick-up and assisted-reproductive techniques. In clinical trials, Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.
Therapeutic Area (MeSH)
N/AATC Code
H01CC02
ATC Item
cetrorelix
Pharmacotherapeutic Group
Pituitary and hypothalamic hormones and analogues
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| cetrorelix (as acetate) | N/A | cetrorelix (as acetate) |
EMA Name
Cetrotide
Medicine Name
Cetrotide
Aliases
N/ANo risk management plan link.
